Drug-induced liver injury: Summary of a single topic clinical research conference

Authors


  • Potential conflict of interest: Dr. Watkins is on the advisory board for GlaxoSmithKline and is a consultant for Actelion, Critical Therapeutics, CSL, Encysive, Hoffmann-LaRoche, Valiant, VIA.

Abstract

Idiosyncratic drug induced liver injury (DILI) remains poorly understood. It is assumed that the affected individuals possess a rare combination of genetic and non genetic factors that, if identified, would greatly improve understanding of the underlying mechanisms. This single topic conference brought together basic scientists, translational investigators, and clinicians with an interest in DILI. The goal was to define high priority areas of investigation that will soon be made possible by The Drug-Induced Liver Injury Network (DILIN). Since 2004 DILIN has been collecting clinical data, genomic DNA and some tissues from patients who have experienced bone fide DILI. The presentations spanned many different areas of DILI, and included novel data concerning mechanisms of hepatotoxicity, new “omics” approaches, and the challenges of improving causation assessment. (HEPATOLOGY 2006;43:618–631.)

Ancillary